^
Association details:
| Biomarker: | MSI-L/dMMR |
|---|---|
| Cancer: | Small Intestinal Carcinoma |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/10/2021
Excerpt:
Small Bowel Adenocarcinoma...Systemic Therapy for Advanced or Metastatic Disease...Dostarlimab-gxly added as a subsequent therapy option for dMMR/MSI-H...
